Frequency and risk factors associated with non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus;Frequência e fatores de risco associados à doença hepática gordurosa não alcoólica em pacientes com diabetes melito tipo 2

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 54, Issue 4, 2010, Pages 362-368

  Ferreira, Vera S G ^a   Pernambuco, Ricardo B ^a   Lopes, Edmundo P ^a   Morais, Clarice N ^b   Rodrigues, Marbiana C ^a   Arruda, Maria Juliana ^a   Silva, Lidiane Moura e ^a   Vilar, Lucio ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Diabetes mellitus; HOMA IR; Insulin resistance; NAFLD; TNF

Indexed keywords

EID: 77956440908     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302010000400004     Document Type: Article

References (43)

1. Bellentani S, Marino M. Epidemiology and natural history of nonalcoholic fatty liver disease (NAFLD). Ann Hepatol. 2009;8(1):S4-8.
2. Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007;30(3): 734-43.
3. BRASIL. Ministério da Saúde. Multicenter study about the prevalence of diabetes mellitus in Brazil. Accessed on: 2009 Mar 3. Available from: http://bases.bireme.br.
4. Wild S, Roglic G, Green A, Scref R, King H. Global prevalence of diabetes. Diabetes Care. 2004;27(5):1047-53.
5. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;37(5):1202-19.
6. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ. 2005;172(7):899-905.
7. Wang Y, Zhou M, Lam K, Xu A. Protective roles of adiponectin in obesity-related fatty liver diseases: mechanisms and therapeutic implications. Arq Bras Endocrinol Metabol. 2009;53(2):201-12.
8. Bugianesi E, Bellentani S, Bedogni G, Tiribelli C, Sigliat-Baroni G, Crocè LS, et al. Clinical update on non-alcoholic fatty liver disease and steatohepatitis. Ann Hepatol. 2008;7(2):157-60.
9. Amarapurkar DN, Amarapurkar AD, Patel ND, Agal S, Baigal R, Gupte P, et al. Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver disease. Ann Hepatol. 2006;5(1):30-3.
10. Prashanth M, Ganesh HK, Vimal MV, John M, Bangdar T, Joshi SR, et al. Prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. JAPI 2009;57(3):205-10.
11. Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA. Liver cirrhosis and diabetes: risk factores, pathophisiology, clinical implications and managment. World J Gastroenterol. 2009;15(3):280-8.
12. Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes: The Verona Diabetes Study. Diabetes Care. 1999;22(5):756-61.
13. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30(5):1212-8.
14. Lautämaki R, Borra R, Iozzo P, Komu M, Lehtimaki T, Salmi M, et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. Am J Physiol Enddocrinol Metab. 2006;291(2):E282-90.
15. Targher G, Bertolini L, Rodella S, Zoppin G, Lippi G, Day C, Muggeo M. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia. 2008;51(3):444-50.
16. Chew GT, Gan SK, Watts GF. Revisiting the metabolic syndrome. MJA. 2006;185(8):445-9.
17. International Diabetes Federation 2005. IDF Consensus Worldwide Definition of the Metabolic Syndrome. Accessed on: Mar 23 2009. Available from: http://www.idf.org.br.
18. Hamer WO, Aguirre DA, Casola G, Lavine JE, Woenckhaus M, Sirlin CB. Fatty liver: imaging patterns and pitfalls. Radiographics. 2006;26(6):1637-53.
19. Zander R, Lang W, Wolf HU. Alkaline haematin D-575, a new tool for the determination of haemoglobin as an alternative to the cyanhaemiglobin method. I. Description of the method. Clin Chim Acta. 1984;136(1):83-93.
20. Geloneze B, Vasques AC, Stable CF, Pareja JC, Rosado LE, Queiroz EC, et al. HOMA1-IR and HOMA2-IR indexes in identifying insulin resistance and metabolic syndrome: Brazilian Metabolic Syndrome Study (BRAMS). Arq Bras Endocrinol Metabol. 2009;53(2):281-7.
21. McCullough AJ. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol. 2002;34(3):255-62.
22. Marchesini G, Brizi M, Bianchi G, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999(5);107:450-5.
23. Hamaguchi M, Kojima T, Itoh Y, Yuichi H, Kota F, Tomoaki N, et al. The severity of ultrasonographic finding in nonalcoholilic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol. 2007;102(12):2708-15.
24. Schreuder T, Verwer BJ, van Nieuwkerk MJC, Mulder JJC. Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment. World J Gastroenterol. 2008;14(16):2474-86.
25. Kang H, Greenson JK, Omo JT, Chao C, Peterman D, Anderson L, et al. Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. Am J Gastroenterol. 2006;101(10):2247-53.
26. Bedogni G, Miglioli L, Matsutti F, Tiribelli C, Marchesini G, Bellentani. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 2005;42(1):44-52.
27. Lizardi-Cevera L, Aguilar-Zapata D. Nonalcoholic fatty liver disease and its association with cardiovascular disease. Ann Hepatol. 2009;8(1):S40-3.
28. Tarantino G. Should nonalcoholic fatty liver disease be regarded as a hepatic illness only? World J Gastroenterol. 2007;13(35):4669-72.
29. Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28(1):27-38.
30. Poynard T, Ratziu V, Charlotte F, Messous D, Munteanu M, Imbert-Bismut F, et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006;6(11):34-50.
31. Adiels M, Olofsson SO, Taskinen MR, Boren J. Diabetic dyslipidaemia. Current Opin Lipidol. 2005;16:421-7.
32. Toledo GF, Sniderman DA, Kelley ED. Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes. Diabetes Care. 2006;29(8):1845-50.
33. Li Y, Xu C, Yu C, Xu L, Miao M. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J Hepatol. 2009;50(5):1029-34.
34. Fenkci S, Rota S, Sabir N, Akdag B. Ultrasonographic and biochemical evaluation of visceral obesity in obese women with nonalcoholic fatty liver disease. Eur J Med Res. 2007;12(2):68-73.
35. Baba T, Amasaki Y, Soda M, Hida A, Imaizumi M, Nakashima E, et al. Fatty liver and acid uric levels predict incident coronary heart disease but not stroke among atomic bomb survivous in Nagasaki. Hypertens Res. 2007;30(9):823-9.
36. Liangpunsakul S, Chalasani N. Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the Third National Health and Nutrition Survey (NHANES III). Am J Med Sci. 2005;32(3):111-6.
37. Prati D, Taioli E, Zanalla A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Int Med. 2002;137(1):1-9.
38. Stranges S, Trevisan M, Dorn JM, Dmochowski J, Donahue RP. Body distribution, liver enzymes, and risk of hypertension: evidence from the Western New York Study. Hypertension. 2005;46(5):1186-93.
39. Trombini P, Piperno A. Ferritin, metabolic syndrome and NAFLD: elective attractions and dangerous liasions. J Hepatol. 2007;46(4):549-52.
40. Lyssenko V, Almgren P, Anevski D, Perfekt R, Lahti K, Nissén M, et al. Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes. 2005;54(1):166-74.
41. Wajchenberg BL, Nery M, Cunha MR, Silva ME. Adipose tissue at the crossroads in the development of the metabolic sindrome, inflammation and aterosclerosis. Arq Bras Endocrinol Metabol. 2009;53(2):145-50.
42. Perez-Carreras M, Del Hoyo P, Marti MA, Rubio CJ, Martin A, Castellano G, et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology. 2003;38(4):999-1007.
43. Aller R, de Luis DA, Fernandez L, Calle F, Velayos B, Olcos JL, et al. Influence of insulin resistance and adipokines in the grade of steatosis of nonalcoholic fatty liver disease. Dig Dis Sci. 2008;53(4):1088-92.